Related Articles by Review for PMID: 23182148

Year	Number of Results
2005	1
2007	2
2009	2
2010	2
2011	6
2012	4
2013	6
2014	2
2015	2
2016	1
2020	2
2021	1
2024	0

1

The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer.

Blackhall F, Thatcher N, Booton R, Kerr K. Blackhall F, et al. Lung Cancer. 2013 Feb;79(2):101-3. doi: 10.1016/j.lungcan.2012.10.016. Epub 2012 Nov 22. Lung Cancer. 2013. PMID: 23182148 Review.

2

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.

Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E. Pilotto S, et al. Expert Opin Pharmacother. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9. Expert Opin Pharmacother. 2013. PMID: 23472711 Review.

3

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.

Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gridelli C, et al. Lung Cancer. 2011 Mar;71(3):249-57. doi: 10.1016/j.lungcan.2010.12.008. Epub 2011 Jan 8. Lung Cancer. 2011. PMID: 21216486 Review.

4

Personalized medicine for non-small-cell lung cancer.

Mok TS, Zhou Q, Leung L, Loong HH. Mok TS, et al. Expert Rev Anticancer Ther. 2010 Oct;10(10):1601-11. doi: 10.1586/era.10.76. Expert Rev Anticancer Ther. 2010. PMID: 20942631 Review.

5

Personalized targeted therapy in advanced non-small cell lung cancer.

Ma PC. Ma PC. Cleve Clin J Med. 2012 May;79 Electronic Suppl 1:eS56-60. doi: 10.3949/ccjm.79.s2.12. Cleve Clin J Med. 2012. PMID: 22614968 Free article. Review.

6

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.

Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gridelli C, et al. Lung Cancer. 2011 Apr;72(1):3-8. doi: 10.1016/j.lungcan.2010.12.009. Epub 2011 Jan 8. Lung Cancer. 2011. PMID: 21216488 Review.

7

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

John T, Liu G, Tsao MS. John T, et al. Oncogene. 2009 Aug;28 Suppl 1:S14-23. doi: 10.1038/onc.2009.197. Oncogene. 2009. PMID: 19680292 Review.

8

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Sequist LV, Bell DW, Lynch TJ, Haber DA. Sequist LV, et al. J Clin Oncol. 2007 Feb 10;25(5):587-95. doi: 10.1200/JCO.2006.07.3585. J Clin Oncol. 2007. PMID: 17290067 Review.

9

The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.

D'Arcangelo M, Wynes MW, Hirsch FR. D'Arcangelo M, et al. Curr Opin Oncol. 2013 Mar;25(2):121-9. doi: 10.1097/CCO.0b013e32835d8175. Curr Opin Oncol. 2013. PMID: 23385859 Review.

10

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.

Santarpia M, Altavilla G, Salazar MF, Magri I, Pettineo G, Benecchi S, Rosell R. Santarpia M, et al. Expert Rev Respir Med. 2011 Jun;5(3):413-24. doi: 10.1586/ers.11.27. Expert Rev Respir Med. 2011. PMID: 21702662 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

28 results

Results by year